Agenus (AGEN) Catches Eye: Stock Adds 8.8% in Session
Agenus Inc. AGEN was a big mover last session, as the company saw its shares rise almost 9% on the day. The stock rallied after the Food and Drug Administration approved the company’s investigational new drug application. This also led to far more shares changing hands than in a normal session. This reverses the downtrend for the company, as the stock is down nearly 22% in the past one-month time frame.
The company has not seen any estimate revision in the past 30 days and its Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Agenus currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked biomedical stock is Anika Therapeutics Inc. ANIK with a Zacks Rank #1 (Strong Buy).
Is AGEN going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AGENUS INC (AGEN): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
To read this article on Zacks.com click here.
